Shenzhou Cell: SCT640C Injection Receives Approval Notice for Drug Clinical Trials.

Shenzhou Cell Announcement, recently, the holding subsidiary Shenzhou Cell Engineering Co., Ltd. received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration, approving the company's independently developed product SCT640C injection to conduct clinical trials for the indication of adult rheumatoid arthritis.